Lipoprotein(a) and its Significance in Cardiovascular Disease

Repeat Measures of Lipoprotein(a) Molar Concentration and Cardiovascular Risk

(2022) Mark Trinder et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)

(2022) Michael J. Koren et al.   NATURE MEDICINE

Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels

(2022) Steven E. Nissen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Independent Association of Lipoprotein(a) and Coronary Artery Calcification With Atherosclerotic Cardiovascular Risk

(2022) Anurag Mehta et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult

(2021) Glen J. Pearson et al.   CANADIAN JOURNAL OF CARDIOLOGY

The impact of race and ethnicity on lipoprotein(a) levels and cardiovascular risk

(2021) Gissette Reyes-Soffer   CURRENT OPINION IN LIPIDOLOGY

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

(2021) Gregory G. Schwartz et al.   DIABETES CARE

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

(2021) Frank L J Visseren et al.   EUROPEAN HEART JOURNAL

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

(2021) Gregory G. Schwartz et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

(2020) Vera A. Bittner et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

(2020) Sotirios Tsimikas et al.   NEW ENGLAND JOURNAL OF MEDICINE

The dedicated “Lp(a) clinic”: A concept whose time has arrived?

(2020) Sotirios Tsimikas et al.   ATHEROSCLEROSIS

An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial

(2020) Brian A. Bergmark et al.   JAMA Cardiology

Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias

(2020) Julius L. Katzmann et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lipoprotein(a) and calcific aortic valve stenosis: A systematic review

(2020) Raviteja R. Guddeti et al.   PROGRESS IN CARDIOVASCULAR DISEASES

Diet and Lp(a): Does Dietary Change Modify Residual Cardiovascular Risk Conferred by Lp(a)?

(2020) Byambaa Enkhmaa et al.   Nutrients

EXPRESS: Lp(a): when and how to measure it

(2020) Jaimini Cegla et al.   ANNALS OF CLINICAL BIOCHEMISTRY

Lipoprotein(a) and Cardiovascular Disease

(2020) Pia R Kamstrup   CLINICAL CHEMISTRY

Lipoprotein (a) and diabetes mellitus

(2020) Natalie C. Ward et al.   Current Opinion in Endocrinology Diabetes and Obesity

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

(2019) Michelle L. O'Donoghue et al.   CIRCULATION

Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia

(2019) Katrina L. Ellis et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Statin therapy increases lipoprotein(a) levels

(2019) Sotirios Tsimikas et al.   EUROPEAN HEART JOURNAL

Use of lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. Don P. Wilson, MD, on behalf of the Writing group

(2019) Don P. Wilson et al.   Journal of Clinical Lipidology

The role of lipoprotein (a) in primary and secondary cardiovascular disease prevention

(2019) Matina Kouvari et al.   CURRENT OPINION IN CARDIOLOGY

Elevated Lipoprotein(a) and Risk of Ischemic Stroke

(2019) Anne Langsted et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention

(2019) Christian M. Madsen et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

HEART UK consensus statement on Lipoprotein(a): A call to action

(2019) Jaimini Cegla et al.   ATHEROSCLEROSIS

Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes

(2019) Daniel F. Gudbjartsson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies

(2018) Stephen Burgess et al.   JAMA Cardiology

Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials

(2018) Peter Willeit et al.   LANCET

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

(2018) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium

(2017) Christoph Waldeyer et al.   EUROPEAN HEART JOURNAL

Trends in Testing for Lipoprotein(a) at an Academic Medical Center Over 13 Years

(2017) Michael Wilkinson et al.   Journal of Clinical Lipidology

A Test in Context: Lipoprotein(a)

(2017) Sotirios Tsimikas   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United StatesHighlights

(2016) Steve Varvel et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Structure, function, and genetics of lipoprotein (a)

(2016) Konrad Schmidt et al.   JOURNAL OF LIPID RESEARCH

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

(2016) Nicholas J Viney et al.   LANCET

Impact of Lipoprotein(a) as Residual Risk on Long-Term Outcomes in Patients After Percutaneous Coronary Intervention

(2015) Hirokazu Konishi et al.   AMERICAN JOURNAL OF CARDIOLOGY

Race Is a Key Variable in Assigning Lipoprotein(a) Cutoff Values for Coronary Heart Disease Risk AssessmentSignificance

(2015) Weihua Guan et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Elevated Lipoprotein(a) Does Not Cause Low-Grade Inflammation Despite Causal Association With Aortic Valve Stenosis and Myocardial Infarction: A Study of 100 578 Individuals from the General Population

(2015) Anne Langsted et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Lipoprotein (a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis

(2015) George Thanassoulis   JOURNAL OF LIPID RESEARCH

Lipoprotein (a): impact by ethnicity and environmental and medical conditions

(2015) Byambaa Enkhmaa et al.   JOURNAL OF LIPID RESEARCH

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study

(2015) Sotirios Tsimikas et al.   LANCET

A Common LPA Null Allele Associates With Lower Lipoprotein(a) Levels and Coronary Artery Disease Risk

(2014) Theodosios Kyriakou et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Lipoprotein(a) Levels, Genotype, and Incident Aortic Valve Stenosis: A Prospective Mendelian Randomization Study and Replication in a Case-Control Cohort

(2014) B. J. Arsenault et al.   Circulation-Cardiovascular Genetics

Discrimination and Net Reclassification of Cardiovascular Risk With Lipoprotein(a)

(2014) Peter Willeit et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Distribution and Medical Impact of Loss-of-Function Variants in the Finnish Founder Population

(2014) Elaine T. Lim et al.   PLoS Genetics

Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk

(2013) Amit V. Khera et al.   CIRCULATION

Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes

(2013) John J. Albers et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease

(2013) Michelle L. O'Donoghue et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population

(2013) Pia R. Kamstrup et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Large-scale association analysis identifies new risk loci for coronary artery disease

(2012) Panos Deloukas et al.   NATURE GENETICS

Lipoprotein(a) as a cardiovascular risk factor: current status

(2010) Børge G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction

(2009) Pia R. Kamstrup   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality

(2009)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease

(2009) Robert Clarke et al.   NEW ENGLAND JOURNAL OF MEDICINE

Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population

(2007) Pia R. Kamstrup et al.   CIRCULATION